Trizell Ltd. engages in research and experimental development on biotechnology. The company was founded on April 14, 1997 and is headquartered in Chinnor, the United Kingdom.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; an Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; and an RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We are supported by a strong network of industry, governmental agencies and academic collaborators and have received over $5.0 million in equity and non-dilutive funding (NIH, IRS grants and programs). Our portfolio of vaccine candidates has a prospective addressable market of over US$5 billion in annual worldwide sales. Our IP is strong and protected by multiple domestic and international patent applications. We are actively pursuing strategic alliances, licensing arrangements and collaborations in order to bring our products closer to the market. We are seeking funding to start human testing of 1 to 3 vaccine candidates.

Huvepharma AD, along with its subsidiaries, develops, manufactures, and markets human and animal health products. It offers medicated food additives, such as anticoccidials and anti-infectives. The company also provides veterinary products, including vitamin and mineral pre-mixes, injections, tablets, and oral solutions. In addition, it offers feed additives, such as enzymes and microflora managers, as well as APIs for veterinary and human use. The company is based in Sofia, Bulgaria. It has offices and subsidiaries in Bulgaria, Belgium, Poland, Thailand, the United States, Taiwan, China, and the Russian Federation. Huvepharma AD operates as a subsidiary of Napredak Holding Ad.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration. Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.

Shanghai WuXi Biotechnology Co., Ltd., established on 2015-01-06, Business scope includes licensed projects:pharmaceutical production;Drug import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Engaged in technology development in the field of biomedical technology,technical consulting,Technical Services,technology transfer;Engaged in the import and export of goods and technology,Re-export trade,Trade and trade agency between enterprises in the region,Class I medical device,Sales of Class II Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shenzhen Boao Kang Biotechnology Co., Ltd., established on 2013-11-04, Business scope includes general business items:Research on Biotechnology Products,Biological product,biotechnology products,Development of biochemical scientific research reagents and related technical services,Biochemical Research Instruments,Reagent,Sales of laboratory consumables;Operating Class II medical devices;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

Guangzhou PackGene Biotech Co., Ltd. (doing business as Packgene) is a Chinese company located in Guangzhou that develops adeno-associated viruses. It was founded in 2014 by Hua Peng Li and Cheng Quan Han. Chao Zhang is currently the CEO of the firm.\nThe company says this about itself: PackGene is a world-leading Adeno-Associated Virus (AAV) vector CRO and CDMO company, providing economical, reliable, and scalable plasmid DNA and AAV viral vector production for early-stage drug discovery, preclinical development, and clinical trials for Cell and Gene Therapy (CGT). The proprietary ?-Alpha? 293 AAV High-Yield Platform uses uniquely designed RC plasmid in the triple-plasmid transfection system to increase AAV production by three to eight times in various AAV serotypes.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Nanjing Jidan Bio-Pharmaceutical Co., Ltd., established on 2012-04-06, Business scope includes biological,Biochemical reagents(Except for license matters)sales and technical consultation;Biomedical Engineering Technology,Technology development related to bio-agricultural engineering,R&D services and R&D of related technical products;Sell ​​self-produced products(Except for license matters)and technical advice;electronic computer software,Production of hardware and its accessories,Sales;Sales of medical devices and related technical support;electronic product,Equipment,Instrumentation,Sales and technical consultation of laboratory consumables;Instrument rental;Biotechnology Extension Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

Research Development Foundation is an American private company that operates as noncommercial research organizations.